Feedback / Questions
FB849 - 1ST Bio
https://www.biospace.com/article/releases/1st-biotherapeutics-inc-announces-first-patient-dosed-in-phase-i-ii-study-of-hpk1-inhibitor-fb849-in-patients-with-advanced-solid-tumors/
Dec 14, 2023
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next